{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:53:57Z","timestamp":1789786437485,"version":"4.0.1"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2011,4,26]],"date-time":"2011-04-26T00:00:00Z","timestamp":1303776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2011,4,26]],"date-time":"2011-04-26T00:00:00Z","timestamp":1303776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Psychiatry"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1038\/mp.2011.28","type":"journal-article","created":{"date-parts":[[2011,4,26]],"date-time":"2011-04-26T08:03:15Z","timestamp":1303804995000},"page":"889-902","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["The role of immunity in Huntington's disease"],"prefix":"10.1038","volume":"16","author":[{"given":"D","family":"Soulet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Cicchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,4,26]]},"reference":[{"key":"BFmp201128_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1474-4422(09)70178-4","volume":"8","author":"JM van der Burg","year":"2009","unstructured":"van der Burg JM, Bjorkqvist M, Brundin P . Beyond the brain: widespread pathology in Huntington's disease. Lancet Neurol 2009; 8: 765\u2013774.","journal-title":"Lancet Neurol"},{"key":"BFmp201128_CR2","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2174\/156652407781695738","volume":"7","author":"BL Wright","year":"2007","unstructured":"Wright BL, Barker RA . Established and emerging therapies for Huntington\u2032s disease. Curr Mol Med 2007; 7: 579\u2013587.","journal-title":"Curr Mol Med"},{"key":"BFmp201128_CR3","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1002\/mds.21971","volume":"23","author":"W Phillips","year":"2008","unstructured":"Phillips W, Shannon KM, Barker RA . The current clinical management of Huntington\u2032s disease. Mov Disord 2008; 23: 1491\u20131504.","journal-title":"Mov Disord"},{"key":"BFmp201128_CR4","doi-asserted-by":"publisher","first-page":"561","DOI":"10.2165\/11534430-000000000-00000","volume":"70","author":"S Frank","year":"2010","unstructured":"Frank S, Jankovic J . Advances in the pharmacological management of Huntington\u2032s disease. Drugs 2010; 70: 561\u2013571.","journal-title":"Drugs"},{"key":"BFmp201128_CR5","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1111\/j.1460-9568.2008.06310.x","volume":"27","author":"JM Gil","year":"2008","unstructured":"Gil JM, Rego AC . Mechanisms of neurodegeneration in Huntington\u2032s disease. Eur J Neurosci 2008; 27: 2803\u20132820.","journal-title":"Eur J Neurosci"},{"key":"BFmp201128_CR6","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1007\/s00018-006-6242-0","volume":"63","author":"M Borrell-Pages","year":"2006","unstructured":"Borrell-Pages M, Zala D, Humbert S, Saudou F . Huntington\u2032s disease: from huntingtin function and dysfunction to therapeutic strategies. Cell Mol Life Sci 2006; 63: 2642\u20132660.","journal-title":"Cell Mol Life Sci"},{"key":"BFmp201128_CR7","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1097\/01.WCB.0000044631.80210.3C","volume":"23","author":"Y Chen","year":"2003","unstructured":"Chen Y, Swanson RA . Astrocytes and brain injury. J Cereb Blood Flow Metab 2003; 23: 137\u2013149.","journal-title":"J Cereb Blood Flow Metab"},{"key":"BFmp201128_CR8","doi-asserted-by":"publisher","first-page":"R506","DOI":"10.1016\/j.cub.2008.04.047","volume":"18","author":"D Soulet","year":"2008","unstructured":"Soulet D, Rivest S . Microglia. Curr Biol 2008; 18: R506\u2013R508.","journal-title":"Curr Biol"},{"key":"BFmp201128_CR9","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1126\/science.1118948","volume":"310","author":"F Nimmerjahn","year":"2005","unstructured":"Nimmerjahn F, Ravetch JV . Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 2005; 310: 1510\u20131512.","journal-title":"Science"},{"key":"BFmp201128_CR10","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1097\/00005072-198511000-00003","volume":"44","author":"JP Vonsattel","year":"1985","unstructured":"Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr . Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44: 559\u2013577.","journal-title":"J Neuropathol Exp Neurol"},{"key":"BFmp201128_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/jnen\/60.2.161","volume":"60","author":"E Sapp","year":"2001","unstructured":"Sapp E, Kegel KB, Aronin N, Hashikawa T, Uchiyama Y, Tohyama K et al. Early and progressive accumulation of reactive microglia in the Huntington disease brain. J Neuropathol Exp Neurol 2001; 60: 161\u2013172.","journal-title":"J Neuropathol Exp Neurol"},{"key":"BFmp201128_CR12","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.brainresbull.2006.10.029","volume":"72","author":"YF Tai","year":"2007","unstructured":"Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ et al. Imaging microglial activation in Huntington's disease. Brain Res Bull 2007; 72: 148\u2013151.","journal-title":"Brain Res Bull"},{"key":"BFmp201128_CR13","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/hbm.21008","volume":"32","author":"M Politis","year":"2011","unstructured":"Politis M, Pavese N, Tai YF, Kiferle L, Mason SL, Brooks DJ et al. Microglial activation in regions related to cognitive function predicts disease onset in Huntington\u2032s disease: a multimodal imaging study. Hum Brain Mapp 2011; 32: 258\u2013270.","journal-title":"Hum Brain Mapp"},{"key":"BFmp201128_CR14","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.nbd.2009.10.015","volume":"37","author":"N Pavese","year":"2010","unstructured":"Pavese N, Politis M, Tai YF, Barker RA, Tabrizi SJ, Mason SL et al. Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. Neurobiol Dis 2010; 37: 356\u2013361.","journal-title":"Neurobiol Dis"},{"key":"BFmp201128_CR15","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s00702-010-0430-7","volume":"117","author":"T Moller","year":"2010","unstructured":"Moller T . Neuroinflammation in Huntington's disease. J Neural Transm 2010; 117: 1001\u20131008.","journal-title":"J Neural Transm"},{"key":"BFmp201128_CR16","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1084\/jem.20080178","volume":"205","author":"M Bjorkqvist","year":"2008","unstructured":"Bjorkqvist M, Wild EJ, Thiele J, Silvestroni A, Andre R, Lahiri N et al. A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease. J Exp Med 2008; 205: 1869\u20131877.","journal-title":"J Exp Med"},{"key":"BFmp201128_CR17","doi-asserted-by":"publisher","first-page":"e4962","DOI":"10.1371\/journal.pone.0004962","volume":"4","author":"N Saleh","year":"2009","unstructured":"Saleh N, Moutereau S, Durr A, Krystkowiak P, Azulay JP, Tranchant C et al. Neuroendocrine disturbances in Huntington's disease. PLoS One 2009; 4: e4962.","journal-title":"PLoS One"},{"key":"BFmp201128_CR18","doi-asserted-by":"publisher","first-page":"10887","DOI":"10.1073\/pnas.0409283102","volume":"102","author":"H Mukai","year":"2005","unstructured":"Mukai H, Isagawa T, Goyama E, Tanaka S, Bence NF, Tamura A et al. Formation of morphologically similar globular aggregates from diverse aggregation-prone proteins in mammalian cells. Proc Natl Acad Sci USA 2005; 102: 10887\u201310892.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFmp201128_CR19","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/1531-8249(200101)49:1<29::AID-ANA7>3.0.CO;2-B","volume":"49","author":"E Gomez-Tortosa","year":"2001","unstructured":"Gomez-Tortosa E, MacDonald ME, Friend JC, Taylor SA, Weiler LJ, Cupples LA et al. Quantitative neuropathological changes in presymptomatic Huntington\u2032s disease. Ann Neurol 2001; 49: 29\u201334.","journal-title":"Ann Neurol"},{"key":"BFmp201128_CR20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1093\/hmg\/8.5.813","volume":"8","author":"K Sathasivam","year":"1999","unstructured":"Sathasivam K, Hobbs C, Turmaine M, Mangiarini L, Mahal A, Bertaux F et al. Formation of polyglutamine inclusions in non-CNS tissue. Hum Mol Genet 1999; 8: 813\u2013822.","journal-title":"Hum Mol Genet"},{"key":"BFmp201128_CR21","doi-asserted-by":"publisher","first-page":"e8025","DOI":"10.1371\/journal.pone.0008025","volume":"4","author":"H Moffitt","year":"2009","unstructured":"Moffitt H, McPhail GD, Woodman B, Hobbs C, Bates GP . Formation of polyglutamine inclusions in a wide range of non-CNS tissues in the HdhQ150 knock-in mouse model of Huntington's disease. PLoS One 2009; 4: e8025.","journal-title":"PLoS One"},{"key":"BFmp201128_CR22","doi-asserted-by":"publisher","first-page":"22480","DOI":"10.1073\/pnas.0911503106","volume":"106","author":"J Bradford","year":"2009","unstructured":"Bradford J, Shin JY, Roberts M, Wang CE, Li XJ, Li S . Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci USA 2009; 106: 22480\u201322485.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFmp201128_CR23","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1083\/jcb.200508072","volume":"171","author":"JY Shin","year":"2005","unstructured":"Shin JY, Fang ZH, Yu ZX, Wang CE, Li SH, Li XJ . Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol 2005; 171: 1001\u20131012.","journal-title":"J Cell Biol"},{"key":"BFmp201128_CR24","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1006\/nbdi.2001.0430","volume":"8","author":"JC Lievens","year":"2001","unstructured":"Lievens JC, Woodman B, Mahal A, Spasic-Boscovic O, Samuel D, Kerkerian-Le Goff L et al. Impaired glutamate uptake in the R6 Huntington\u2032s disease transgenic mice. Neurobiol Dis 2001; 8: 807\u2013821.","journal-title":"Neurobiol Dis"},{"key":"BFmp201128_CR25","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1093\/brain\/awf180","volume":"125","author":"PF Behrens","year":"2002","unstructured":"Behrens PF, Franz P, Woodman B, Lindenberg KS, Landwehrmeyer GB . Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 2002; 125: 1908\u20131922.","journal-title":"Brain"},{"key":"BFmp201128_CR26","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12035-009-8097-5","volume":"41","author":"HY Hsiao","year":"2010","unstructured":"Hsiao HY, Chern Y . Targeting glial cells to elucidate the pathogenesis of Huntington's disease. Mol Neurobiol 2010; 41: 248\u2013255.","journal-title":"Mol Neurobiol"},{"key":"BFmp201128_CR27","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s11064-007-9463-1","volume":"33","author":"B Hassel","year":"2008","unstructured":"Hassel B, Tessler S, Faull RL, Emson PC . Glutamate uptake is reduced in prefrontal cortex in Huntington's disease. Neurochem Res 2008; 33: 232\u2013237.","journal-title":"Neurochem Res"},{"key":"BFmp201128_CR28","first-page":"641","volume":"34","author":"F Cicchetti","year":"2010","unstructured":"Cicchetti F, Soulet D, Freeman TB . Neuronal degeneratin in striatal transplants and Huntington's disease: potential mechanisms and clinical implications. Brain 2010; 34: 641\u2013652.","journal-title":"Brain"},{"key":"BFmp201128_CR29","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/00005072-199704000-00013","volume":"56","author":"T Arzberger","year":"1997","unstructured":"Arzberger T, Krampfl K, Leimgruber S, Weindl A . Changes of NMDA receptor subunit (NR1, NR2B) and glutamate transporter (GLT1) mRNA expression in Huntington\u2032s disease--an in situ hybridization study. J Neuropathol Exp Neurol 1997; 56: 440\u2013454.","journal-title":"J Neuropathol Exp Neurol"},{"key":"BFmp201128_CR30","doi-asserted-by":"publisher","first-page":"3277","DOI":"10.1523\/JNEUROSCI.0116-08.2008","volume":"28","author":"SY Chou","year":"2008","unstructured":"Chou SY, Weng JY, Lai HL, Liao F, Sun SH, Tu PH et al. Expanded-polyglutamine huntingtin protein suppresses the secretion and production of a chemokine (CCL5\/RANTES) by astrocytes. J Neurosci 2008; 28: 3277\u20133290.","journal-title":"J Neurosci"},{"key":"BFmp201128_CR31","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0167-5699(99)01512-1","volume":"21","author":"F Aloisi","year":"2000","unstructured":"Aloisi F, Ria F, Adorini L . Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes. Immunol Today 2000; 21: 141\u2013147.","journal-title":"Immunol Today"},{"key":"BFmp201128_CR32","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/jnr.20562","volume":"81","author":"SU Kim","year":"2005","unstructured":"Kim SU, de Vellis J . Microglia in health and disease. J Neurosci Res 2005; 81: 302\u2013313.","journal-title":"J Neurosci Res"},{"key":"BFmp201128_CR33","doi-asserted-by":"publisher","first-page":"7527","DOI":"10.4049\/jimmunol.166.12.7527","volume":"166","author":"TM Tikka","year":"2001","unstructured":"Tikka TM, Koistinaho JE . Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol 2001; 166: 7527\u20137533.","journal-title":"J Immunol"},{"key":"BFmp201128_CR34","doi-asserted-by":"publisher","first-page":"10483","DOI":"10.1073\/pnas.1832501100","volume":"100","author":"X Wang","year":"2003","unstructured":"Wang X, Zhu S, Drodza M, Zhang W, Stavrovskaya IG, Cattaneo E et al. Minocycline inhibits caspase-independent and-dependent mitochondrial cell death pathways in models of Huntington's disease. Proc Natl Acad Sci USA 2003; 100: 10483\u201310487.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFmp201128_CR35","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1016\/j.mad.2005.06.012","volume":"126","author":"X Wang","year":"2005","unstructured":"Wang X, Chen S, Ma G, Ye M, Lu G . Involvement of proinflammatory factors, apoptosis, caspase-3 activation and Ca2+ disturbance in microglia activation-mediated dopaminergic cell degeneration. Mech Ageing Dev 2005; 126: 1241\u20131254.","journal-title":"Mech Ageing Dev"},{"key":"BFmp201128_CR36","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1093\/brain\/awp239","volume":"132","author":"J Palazuelos","year":"2009","unstructured":"Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E et al. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington\u2032s disease excitotoxicity. Brain 2009; 132: 3152\u20133164.","journal-title":"Brain"},{"key":"BFmp201128_CR37","doi-asserted-by":"publisher","first-page":"10653","DOI":"10.1074\/jbc.M109.083287","volume":"285","author":"J Bradford","year":"2010","unstructured":"Bradford J, Shin JY, Roberts M, Wang CE, Sheng G, Li S et al. Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. J Biol Chem 2010; 285: 10653\u201310661.","journal-title":"J Biol Chem"},{"key":"BFmp201128_CR38","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1002\/mds.20373","volume":"20","author":"C Saft","year":"2005","unstructured":"Saft C, Zange J, Andrich J, Muller K, Lindenberg K, Landwehrmeyer B et al. Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov Disord 2005; 20: 674\u2013679.","journal-title":"Mov Disord"},{"key":"BFmp201128_CR39","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1006\/exnr.1999.7170","volume":"159","author":"SK Singhrao","year":"1999","unstructured":"Singhrao SK, Neal JW, Morgan BP, Gasque P . Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease. Exp Neurol 1999; 159: 362\u2013376.","journal-title":"Exp Neurol"},{"key":"BFmp201128_CR40","doi-asserted-by":"publisher","first-page":"7999","DOI":"10.1523\/JNEUROSCI.2675-04.2004","volume":"24","author":"A Khoshnan","year":"2004","unstructured":"Khoshnan A, Ko J, Watkin EE, Paige LA, Reinhart PH, Patterson PH . Activation of the IkappaB kinase complex and nuclear factor-kappaB contributes to mutant huntingtin neurotoxicity. J Neurosci 2004; 24: 7999\u20138008.","journal-title":"J Neurosci"},{"key":"BFmp201128_CR41","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1212\/01.wnl.0000312279.49272.9f","volume":"70","author":"H Braak","year":"2008","unstructured":"Braak H, Del Tredici K . Invited article: nervous system pathology in sporadic Parkinson disease. Neurology 2008; 70: 1916\u20131925.","journal-title":"Neurology"},{"key":"BFmp201128_CR42","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","volume":"24","author":"H Braak","year":"2003","unstructured":"Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E . Staging of brain pathology related to sporadic Parkinson\u2032s disease. Neurobiol Aging 2003; 24: 197\u2013211.","journal-title":"Neurobiol Aging"},{"key":"BFmp201128_CR43","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.molmed.2004.01.008","volume":"10","author":"S Haik","year":"2004","unstructured":"Haik S, Faucheux BA, Hauw JJ . Brain targeting through the autonomous nervous system: lessons from prion diseases. Trends Mol Med 2004; 10: 107\u2013112.","journal-title":"Trends Mol Med"},{"key":"BFmp201128_CR44","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1365-2990.2007.00874.x","volume":"33","author":"CH Hawkes","year":"2007","unstructured":"Hawkes CH, Del Tredici K, Braak H . Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 2007; 33: 599\u2013614.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"BFmp201128_CR45","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1111\/j.1582-4934.2008.00450.x","volume":"12","author":"C Roodveldt","year":"2008","unstructured":"Roodveldt C, Christodoulou J, Dobson CM . Immunological features of alpha-synuclein in Parkinson's disease. J Cell Mol Med 2008; 12: 1820\u20131829.","journal-title":"J Cell Mol Med"},{"key":"BFmp201128_CR46","doi-asserted-by":"publisher","first-page":"29691","DOI":"10.1074\/jbc.M705004200","volume":"282","author":"IJ Morten","year":"2007","unstructured":"Morten IJ, Gosal WS, Radford SE, Hewitt EW . Investigation into the role of macrophages in the formation and degradation of beta2-microglobulin amyloid fibrils. J Biol Chem 2007; 282: 29691\u201329700.","journal-title":"J Biol Chem"},{"key":"BFmp201128_CR47","doi-asserted-by":"publisher","first-page":"2905","DOI":"10.1093\/hmg\/11.23.2905","volume":"11","author":"W Yang","year":"2002","unstructured":"Yang W, Dunlap JR, Andrews RB, Wetzel R . Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet 2002; 11: 2905\u20132917.","journal-title":"Hum Mol Genet"},{"key":"BFmp201128_CR48","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/ncb1830","volume":"11","author":"PH Ren","year":"2009","unstructured":"Ren PH, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, Kopito RR . Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol 2009; 11: 219\u2013225.","journal-title":"Nat Cell Biol"},{"key":"BFmp201128_CR49","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1385\/IR:31:3:243","volume":"31","author":"N Qureshi","year":"2005","unstructured":"Qureshi N, Vogel SN, Van Way C III, Papasian CJ, Qureshi AA, Morrison DC . The proteasome: a central regulator of inflammation and macrophage function. Immunol Res 2005; 31: 243\u2013260.","journal-title":"Immunol Res"},{"key":"BFmp201128_CR50","doi-asserted-by":"publisher","first-page":"13285","DOI":"10.1523\/JNEUROSCI.4393-08.2008","volume":"28","author":"S Tydlacka","year":"2008","unstructured":"Tydlacka S, Wang CE, Wang X, Li S, Li XJ . Differential activities of the ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons. J Neurosci 2008; 28: 13285\u201313295.","journal-title":"J Neurosci"},{"key":"BFmp201128_CR51","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0959-4388(00)00134-3","volume":"10","author":"BA Barres","year":"2000","unstructured":"Barres BA, Barde Y . Neuronal and glial cell biology. Curr Opin Neurobiol 2000; 10: 642\u2013648.","journal-title":"Curr Opin Neurobiol"},{"key":"BFmp201128_CR52","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1523\/JNEUROSCI.22-05-01592.2002","volume":"22","author":"RJ Ferrante","year":"2002","unstructured":"Ferrante RJ, Andreassen OA, Dedeoglu A, Ferrante KL, Jenkins BG, Hersch SM et al. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 2002; 22: 1592\u20131599.","journal-title":"J Neurosci"},{"key":"BFmp201128_CR53","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/77528","volume":"6","author":"M Chen","year":"2000","unstructured":"Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S et al. Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 2000; 6: 797\u2013801.","journal-title":"Nat Med"},{"key":"BFmp201128_CR54","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1002\/ana.10614","volume":"54","author":"DL Smith","year":"2003","unstructured":"Smith DL, Woodman B, Mahal A, Sathasivam K, Ghazi-Noori S, Lowden PA et al. Minocycline and doxycycline are not beneficial in a model of Huntington's disease. Ann Neurol 2003; 54: 186\u2013196.","journal-title":"Ann Neurol"},{"key":"BFmp201128_CR55","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1385\/NMM:9:1:47","volume":"9","author":"S Mievis","year":"2007","unstructured":"Mievis S, Levivier M, Communi D, Vassart G, Brotchi J, Ledent C et al. Lack of minocycline efficiency in genetic models of Huntington's disease. Neuromolecular Med 2007; 9: 47\u201354.","journal-title":"Neuromolecular Med"},{"key":"BFmp201128_CR56","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.bbadis.2005.11.002","volume":"1762","author":"EC Stack","year":"2006","unstructured":"Stack EC, Smith KM, Ryu H, Cormier K, Chen M, Hagerty SW et al. Combination therapy using minocycline and coenzyme Q10 in R6\/2 transgenic Huntington's disease mice. Biochim Biophys Acta 2006; 1762: 373\u2013380.","journal-title":"Biochim Biophys Acta"},{"key":"BFmp201128_CR57","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.nbd.2004.07.011","volume":"17","author":"F Norflus","year":"2004","unstructured":"Norflus F, Nanje A, Gutekunst CA, Shi G, Cohen J, Bejarano M et al. Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice. Neurobiol Dis 2004; 17: 319\u2013325.","journal-title":"Neurobiol Dis"},{"key":"BFmp201128_CR58","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.nbd.2004.09.017","volume":"18","author":"K Bantubungi","year":"2005","unstructured":"Bantubungi K, Jacquard C, Greco A, Pintor A, Chtarto A, Tai K et al. Minocycline in phenotypic models of Huntington's disease. Neurobiol Dis 2005; 18: 206\u2013217.","journal-title":"Neurobiol Dis"},{"key":"BFmp201128_CR59","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/j.neuroscience.2006.05.043","volume":"141","author":"JK Ryu","year":"2006","unstructured":"Ryu JK, Choi HB, McLarnon JG . Combined minocycline plus pyruvate treatment enhances effects of each agent to inhibit inflammation, oxidative damage, and neuronal loss in an excitotoxic animal model of Huntington's disease. Neuroscience 2006; 141: 1835\u20131848.","journal-title":"Neuroscience"},{"key":"BFmp201128_CR60","doi-asserted-by":"publisher","first-page":"e9793","DOI":"10.1371\/journal.pone.0009793","volume":"5","author":"LB Menalled","year":"2010","unstructured":"Menalled LB, Patry M, Ragland N, Lowden PA, Goodman J, Minnich J et al. Comprehensive behavioral testing in the R6\/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline. PLoS One 2010; 5: e9793.","journal-title":"PLoS One"},{"key":"BFmp201128_CR61","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1212\/01.WNL.0000049936.85487.7A","volume":"60","author":"RM Bonelli","year":"2003","unstructured":"Bonelli RM, Heuberger C, Reisecker F . Minocycline for Huntington's disease: an open label study. Neurology 2003; 60: 883\u2013884.","journal-title":"Neurology"},{"key":"BFmp201128_CR62","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1097\/00004850-200411000-00004","volume":"19","author":"RM Bonelli","year":"2004","unstructured":"Bonelli RM, Hodl AK, Hofmann P, Kapfhammer HP . Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int Clin Psychopharmacol 2004; 19: 337\u2013342.","journal-title":"Int Clin Psychopharmacol"},{"key":"BFmp201128_CR63","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/mds.20018","volume":"19","author":"M Thomas","year":"2004","unstructured":"Thomas M, Ashizawa T, Jankovic J . Minocycline in Huntington's disease: a pilot study. Mov Disord 2004; 19: 692\u2013695.","journal-title":"Mov Disord"},{"key":"BFmp201128_CR64","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/mds.21199","volume":"22","author":"N Reynolds","year":"2007","unstructured":"Reynolds N . Revisiting safety of minocycline as neuroprotection in Huntington's disease. Mov Disord 2007; 22: 292.","journal-title":"Mov Disord"},{"key":"BFmp201128_CR65","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.bbr.2008.09.040","volume":"196","author":"HS Kim","year":"2009","unstructured":"Kim HS, Suh YH . Minocycline and neurodegenerative diseases. Behav Brain Res 2009; 196: 168\u2013179.","journal-title":"Behav Brain Res"},{"key":"BFmp201128_CR66","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1189\/jlb.0804477","volume":"78","author":"F Giuliani","year":"2005","unstructured":"Giuliani F, Hader W, Yong VW . Minocycline attenuates T cell and microglia activity to impair cytokine production in T cell-microglia interaction. J Leukoc Biol 2005; 78: 135\u2013143.","journal-title":"J Leukoc Biol"},{"key":"BFmp201128_CR67","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1097\/00001756-200410050-00007","volume":"15","author":"Y Song","year":"2004","unstructured":"Song Y, Wei EQ, Zhang WP, Zhang L, Liu JR, Chen Z . Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation. Neuroreport 2004; 15: 2181\u20132184.","journal-title":"Neuroreport"},{"key":"BFmp201128_CR68","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.expneurol.2003.12.006","volume":"186","author":"SC Fagan","year":"2004","unstructured":"Fagan SC, Edwards DJ, Borlongan CV, Xu L, Arora A . Optimal delivery of minocycline to the brain: implication for human studies of acute neuroprotection. Exp Neurol 2004; 186: 248\u2013251.","journal-title":"Exp Neurol"},{"key":"BFmp201128_CR69","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S1570-0232(03)00247-2","volume":"791","author":"M Colovic","year":"2003","unstructured":"Colovic M, Caccia S . Liquid chromatographic determination of minocycline in brain-to-plasma distribution studies in the rat. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 791: 337\u2013343.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"BFmp201128_CR70","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.nbd.2008.11.015","volume":"33","author":"AJ Morton","year":"2009","unstructured":"Morton AJ, Glynn D, Leavens W, Zheng Z, Faull RL, Skepper JN et al. Paradoxical delay in the onset of disease caused by super-long CAG repeat expansions in R6\/2 mice. Neurobiol Dis 2009; 33: 331\u2013341.","journal-title":"Neurobiol Dis"},{"key":"BFmp201128_CR71","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.nbd.2008.10.009","volume":"33","author":"I Dragatsis","year":"2009","unstructured":"Dragatsis I, Goldowitz D, Del Mar N, Deng YP, Meade CA, Liu L et al. CAG repeat lengths &gt; or =335 attenuate the phenotype in the R6\/2 Huntington's disease transgenic mouse. Neurobiol Dis 2009; 33: 315\u2013330.","journal-title":"Neurobiol Dis"},{"key":"BFmp201128_CR72","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0165-6147(00)01884-8","volume":"23","author":"LB Menalled","year":"2002","unstructured":"Menalled LB, Chesselet MF . Mouse models of Huntington's disease. Trends Pharmacol Sci 2002; 23: 32\u201339.","journal-title":"Trends Pharmacol Sci"},{"key":"BFmp201128_CR73","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","volume":"65","author":"DR Langbehn","year":"2004","unstructured":"Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR . A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 2004; 65: 267\u2013277.","journal-title":"Clin Genet"},{"key":"BFmp201128_CR74","doi-asserted-by":"publisher","first-page":"3498","DOI":"10.1073\/pnas.0308679101","volume":"101","author":"NS Wexler","year":"2004","unstructured":"Wexler NS, Lorimer J, Porter J, Gomez F, Moskowitz C, Shackell E et al. Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington\u2032s disease age of onset. Proc Natl Acad Sci USA 2004; 101: 3498\u20133503.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFmp201128_CR75","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/ng0893-387","volume":"4","author":"M Duyao","year":"1993","unstructured":"Duyao M, Ambrose C, Myers R, Novelletto A, Persichetti F, Frontali M et al. Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat Genet 1993; 4: 387\u2013392.","journal-title":"Nat Genet"},{"key":"BFmp201128_CR76","first-page":"225","volume":"61","author":"A Nuti","year":"1991","unstructured":"Nuti A, Maremmani C, Ceravolo R, Pavese N, Bonuccelli U, Muratorio A . Dexamethasone therapy in Huntington chorea: preliminary results. Riv Neurol 1991; 61: 225\u2013227.","journal-title":"Riv Neurol"},{"key":"BFmp201128_CR77","first-page":"149","volume-title":"Advances in Biochemical Psychopharmacology","author":"U Bonucelli","year":"1992","unstructured":"Bonucelli U, Nuti A, Maremmani C, Ceravolo R, Muratorio A . Steroid therapy in Huntington's disease. In: Biggio G, Concas A, Costa E (ed). Advances in Biochemical Psychopharmacology. Rave Press: New York, USA, 1992, pp 149\u2013154."},{"key":"BFmp201128_CR78","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.expneurol.2009.05.012","volume":"219","author":"J Sassone","year":"2009","unstructured":"Sassone J, Colciago C, Cislaghi G, Silani V, Ciammola A . Huntington's disease: the current state of research with peripheral tissues. Exp Neurol 2009; 219: 385\u2013397.","journal-title":"Exp Neurol"},{"key":"BFmp201128_CR79","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.coph.2008.04.002","volume":"8","author":"D Soulet","year":"2008","unstructured":"Soulet D, Rivest S . Bone-marrow-derived microglia: myth or reality? Curr Opin Pharmacol 2008; 8: 508\u2013518.","journal-title":"Curr Opin Pharmacol"},{"key":"BFmp201128_CR80","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.neuron.2009.09.034","volume":"64","author":"M Bjorkqvist","year":"2009","unstructured":"Bjorkqvist M, Wild EJ, Tabrizi SJ . Harnessing immune alterations in neurodegenerative diseases. Neuron 2009; 64: 21\u201324.","journal-title":"Neuron"},{"key":"BFmp201128_CR81","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1093\/brain\/awm044","volume":"130","author":"YF Tai","year":"2007","unstructured":"Tai YF, Pavese N, Gerhard A, Tabrizi SJ, Barker RA, Brooks DJ et al. Microglial activation in presymptomatic Huntington's disease gene carriers. Brain 2007; 130: 1759\u20131766.","journal-title":"Brain"}],"container-title":["Molecular Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/mp201128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/mp201128","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/mp201128.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T02:20:01Z","timestamp":1648779601000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/mp201128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,26]]},"references-count":81,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["BFmp201128"],"URL":"https:\/\/doi.org\/10.1038\/mp.2011.28","relation":{},"ISSN":["1359-4184","1476-5578"],"issn-type":[{"value":"1359-4184","type":"print"},{"value":"1476-5578","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,4,26]]},"assertion":[{"value":"26 September 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2011","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2011","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2011","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}